Last updated Nov 3, 2026
A 50-year-old woman is diagnosed with breast cancer. Her mother had breast cancer at 55, and her maternal uncle had colorectal cancer. Genetic testing reveals a CHEK2 c.1100delC pathogenic variant.
AD; CHEK2 (checkpoint kinase 2, the CHK2 protein); loss of function with moderate penetrance
- DNA damage checkpoint response
- c.1100delC founder variant common in Northern European populations
CHK2 is an effector protein kinase in the ATM-CHK2-p53 DNA damage response: DNA damage activates it, and it halts the cell cycle. CHEK2-related predisposition is loss of function, with a moderate rather than a high risk.
- Truncating variants: c.1100delC (p.Thr367MetfsTer15), common in northern Europe and carried by 1% of the Dutch population, gives a breast cancer odds ratio of 2.66; other truncating variants about 2.1. The excess risk is greatest under age 40 (odds ratio 4.5).
- Missense variants: lower risk overall (odds ratio 1.42 for rare missense variants, with no effect of position). p.Ile157Thr and p.Ser428Phe each carry an odds ratio below 1.5 and are best treated like common risk polymorphisms within a polygenic risk score, not as a single-gene cause; p.Thr476Met may also be low risk.
The cancers differ from those of the homologous recombination genes: they are usually estrogen receptor positive and do not show the genomic signature of homologous recombination deficiency. A variant found at a low allele fraction may reflect clonal hematopoiesis rather than constitutional carriage, and clonal hematopoiesis does not carry the CHEK2 cancer risk, so such a result needs confirmation in another tissue.
- Moderate-penetrance breast cancer gene
- Often hormone receptor-positive breast cancers
- Less severe phenotype than BRCA1/2
- c.1100delC variant creates truncated protein
- Confirmed by germline testing identifying a pathogenic CHEK2 variant, usually on a multigene cancer panel rather than single-gene testing
- The c.1100delC truncating variant is the most common pathogenic allele; missense variants (e.g., p.Ile157Thr) confer lower risk
- Distinguish moderate-penetrance CHEK2 from high-penetrance BRCA1/BRCA2, since management and cascade-testing counseling differ
- Enhanced breast surveillance (earlier mammograms, consider MRI)
- Colonoscopy starting age 40 or 10 years before youngest family diagnosis
- Risk-reducing mastectomy generally NOT recommended (lower penetrance)
- No RRSO recommendation
"CHEK2 = CHEst Kancer from Chr 22": CHEK2 is on chromosome 22 and is associated with breast (chest) cancer.
"CHEK-ERS" checkered pattern: CHEK2 is associated with ER-positive breast cancer. Get a CHEK-up for breast cancer.